MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose. / Booth, Jeremy; Caillet, Vincent; Briggs, Adam; Hardcastle, Nicholas; Angelis, Georgios; Jayamanne, Dasantha; Shepherd, Meegan; Podreka, Alexander; Szymura, Kathryn; Nguyen, Doan Trang; Poulsen, Per; O'Brien, Ricky; Harris, Benjamin; Haddad, Carol; Eade, Thomas; Keall, Paul.

I: Radiotherapy and Oncology, Bind 155, 02.2021, s. 131-137.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Booth, J, Caillet, V, Briggs, A, Hardcastle, N, Angelis, G, Jayamanne, D, Shepherd, M, Podreka, A, Szymura, K, Nguyen, DT, Poulsen, P, O'Brien, R, Harris, B, Haddad, C, Eade, T & Keall, P 2021, 'MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose', Radiotherapy and Oncology, bind 155, s. 131-137. https://doi.org/10.1016/j.radonc.2020.10.036

APA

Booth, J., Caillet, V., Briggs, A., Hardcastle, N., Angelis, G., Jayamanne, D., Shepherd, M., Podreka, A., Szymura, K., Nguyen, D. T., Poulsen, P., O'Brien, R., Harris, B., Haddad, C., Eade, T., & Keall, P. (2021). MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose. Radiotherapy and Oncology, 155, 131-137. https://doi.org/10.1016/j.radonc.2020.10.036

CBE

Booth J, Caillet V, Briggs A, Hardcastle N, Angelis G, Jayamanne D, Shepherd M, Podreka A, Szymura K, Nguyen DT, Poulsen P, O'Brien R, Harris B, Haddad C, Eade T, Keall P. 2021. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose. Radiotherapy and Oncology. 155:131-137. https://doi.org/10.1016/j.radonc.2020.10.036

MLA

Vancouver

Booth J, Caillet V, Briggs A, Hardcastle N, Angelis G, Jayamanne D o.a. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose. Radiotherapy and Oncology. 2021 feb;155:131-137. https://doi.org/10.1016/j.radonc.2020.10.036

Author

Booth, Jeremy ; Caillet, Vincent ; Briggs, Adam ; Hardcastle, Nicholas ; Angelis, Georgios ; Jayamanne, Dasantha ; Shepherd, Meegan ; Podreka, Alexander ; Szymura, Kathryn ; Nguyen, Doan Trang ; Poulsen, Per ; O'Brien, Ricky ; Harris, Benjamin ; Haddad, Carol ; Eade, Thomas ; Keall, Paul. / MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose. I: Radiotherapy and Oncology. 2021 ; Bind 155. s. 131-137.

Bibtex

@article{f8109ad5d91a4d04aa93a81a53588e40,
title = "MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose",
abstract = "Background and purpose: The purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions. Methods and materials: Seventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder–guided MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated with PTV expanded 5 mm from a 4DCT-derived internal target volume (ITV). Treatment was delivered using a standard linear accelerator to continuously adapt the MLC based on transponder motion. Treated volumes and reconstructed delivered dose were compared between MLC tracking and comparator ITV-based treatment. Results: All seventeen patients were successfully treated with MLC tracking (70 successful fractions). MLC tracking treatment delivery time averaged 8 minutes. The time from the start of CBCT to the end of treatment averaged 22 minutes. The MLC tracking PTV for 16/17 patients was smaller than the ITV-based PTV (range −1.6% to 44% reduction, or −0.6 to 18 cc). Reductions in mean lung dose (27 cGy) and V20Gy (50 cc) were statistically significant (p < 0.02). Reconstruction of treatment doses confirmed a statistically significant improvement in delivered GTV D98% (p < 0.05) from planned dose compared with the ITV-based plans. Conclusion: The first treatments with lung MLC tracking have been successfully performed in seventeen SABR patients. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose.",
keywords = "Adaptive radiotherapy, Lung SABR, MLC tracking",
author = "Jeremy Booth and Vincent Caillet and Adam Briggs and Nicholas Hardcastle and Georgios Angelis and Dasantha Jayamanne and Meegan Shepherd and Alexander Podreka and Kathryn Szymura and Nguyen, {Doan Trang} and Per Poulsen and Ricky O'Brien and Benjamin Harris and Carol Haddad and Thomas Eade and Paul Keall",
note = "Funding Information: The authors acknowledge Varian Medical Systems and Royal North Shore Hospital No2 Trust for supporting this study. Publisher Copyright: {\textcopyright} 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2021",
month = feb,
doi = "10.1016/j.radonc.2020.10.036",
language = "English",
volume = "155",
pages = "131--137",
journal = "Radiotherapy & Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd.",

}

RIS

TY - JOUR

T1 - MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose

AU - Booth, Jeremy

AU - Caillet, Vincent

AU - Briggs, Adam

AU - Hardcastle, Nicholas

AU - Angelis, Georgios

AU - Jayamanne, Dasantha

AU - Shepherd, Meegan

AU - Podreka, Alexander

AU - Szymura, Kathryn

AU - Nguyen, Doan Trang

AU - Poulsen, Per

AU - O'Brien, Ricky

AU - Harris, Benjamin

AU - Haddad, Carol

AU - Eade, Thomas

AU - Keall, Paul

N1 - Funding Information: The authors acknowledge Varian Medical Systems and Royal North Shore Hospital No2 Trust for supporting this study. Publisher Copyright: © 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2021/2

Y1 - 2021/2

N2 - Background and purpose: The purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions. Methods and materials: Seventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder–guided MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated with PTV expanded 5 mm from a 4DCT-derived internal target volume (ITV). Treatment was delivered using a standard linear accelerator to continuously adapt the MLC based on transponder motion. Treated volumes and reconstructed delivered dose were compared between MLC tracking and comparator ITV-based treatment. Results: All seventeen patients were successfully treated with MLC tracking (70 successful fractions). MLC tracking treatment delivery time averaged 8 minutes. The time from the start of CBCT to the end of treatment averaged 22 minutes. The MLC tracking PTV for 16/17 patients was smaller than the ITV-based PTV (range −1.6% to 44% reduction, or −0.6 to 18 cc). Reductions in mean lung dose (27 cGy) and V20Gy (50 cc) were statistically significant (p < 0.02). Reconstruction of treatment doses confirmed a statistically significant improvement in delivered GTV D98% (p < 0.05) from planned dose compared with the ITV-based plans. Conclusion: The first treatments with lung MLC tracking have been successfully performed in seventeen SABR patients. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose.

AB - Background and purpose: The purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions. Methods and materials: Seventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder–guided MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated with PTV expanded 5 mm from a 4DCT-derived internal target volume (ITV). Treatment was delivered using a standard linear accelerator to continuously adapt the MLC based on transponder motion. Treated volumes and reconstructed delivered dose were compared between MLC tracking and comparator ITV-based treatment. Results: All seventeen patients were successfully treated with MLC tracking (70 successful fractions). MLC tracking treatment delivery time averaged 8 minutes. The time from the start of CBCT to the end of treatment averaged 22 minutes. The MLC tracking PTV for 16/17 patients was smaller than the ITV-based PTV (range −1.6% to 44% reduction, or −0.6 to 18 cc). Reductions in mean lung dose (27 cGy) and V20Gy (50 cc) were statistically significant (p < 0.02). Reconstruction of treatment doses confirmed a statistically significant improvement in delivered GTV D98% (p < 0.05) from planned dose compared with the ITV-based plans. Conclusion: The first treatments with lung MLC tracking have been successfully performed in seventeen SABR patients. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose.

KW - Adaptive radiotherapy

KW - Lung SABR

KW - MLC tracking

UR - http://www.scopus.com/inward/record.url?scp=85096189207&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2020.10.036

DO - 10.1016/j.radonc.2020.10.036

M3 - Journal article

C2 - 33152399

AN - SCOPUS:85096189207

VL - 155

SP - 131

EP - 137

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

SN - 0167-8140

ER -